Literature DB >> 30780167

Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.

Aaron R Folsom1, Weihong Tang1, Saonli Basu2, Jeffrey R Misialek1, David Couper3, Susan R Heckbert4, Mary Cushman5,6.   

Abstract

The kallikrein/kinin system, an intravascular biochemical pathway that includes several proteins involved in the contact activation system of coagulation, renin-angiotensin activation and inflammation, may or may not play a role in venous thromboembolism (VTE) occurrence. Within a large prospective population-based study in the United States, we conducted a nested case-cohort study to test the hypothesis that higher plasma levels of high molecular weight kininogen (HK) or prekallikrein are associated with greater VTE incidence. We related baseline enzyme-linked immunosorbent assay measures of HK and prekallikrein in 1993 to 1995 to incidence VTE of the lower extremity (n = 612) through 2015 (mean follow-up = 18 years). We found no evidence that plasma HK or prekallikrein was associated positively with incident VTE. HK, in fact, was associated inversely and significantly with VTE in most proportional hazards regression models. For example, the hazard ratio of VTE per standard deviation higher HK concentration was 0.88 (95% confidence interval = 0.81, 0.97), after adjustment for several VTE risk factors. Our findings suggest that plasma levels of these factors do not determine the risk of VTE in the general population. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30780167      PMCID: PMC6499653          DOI: 10.1055/s-0039-1678737

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  29 in total

1.  Kininogens are antithrombotic proteins In vivo.

Authors:  R W Colman; J V White; S Scovell; A Stadnicki; R B Sartor
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

2.  Activated partial thromboplastin time and risk of future venous thromboembolism.

Authors:  Neil A Zakai; Tetsuya Ohira; Richard White; Aaron R Folsom; Mary Cushman
Journal:  Am J Med       Date:  2008-03       Impact factor: 4.965

3.  Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.

Authors:  Christoph Merlo; Walter A Wuillemin; Maurice Redondo; Miha Furlan; Irmela Sulzer; Johanna Kremer-Hovinga; Bernd R Binder; Bernhard Lämmle
Journal:  Atherosclerosis       Date:  2002-04       Impact factor: 5.162

4.  Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo.

Authors:  Sarmina Hassan; Irma M Sainz; Mohammad M Khan; Harlan N Bradford; Irma Isordia-Salas; Sakeen W Kashem; R Balfour Sartor; Robert W Colman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-02-09       Impact factor: 4.733

5.  Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.

Authors:  Sergei Merkulov; Wan-Ming Zhang; Anton A Komar; Alvin H Schmaier; Ellen Barnes; Yihua Zhou; Xincheng Lu; Takayuki Iwaki; Francis J Castellino; Guangbin Luo; Keith R McCrae
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

6.  Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis.

Authors:  Michael J Gallimore; Simon L Harris; David W Jones; Mark Winter
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

7.  A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function.

Authors:  Triantafyllos Chavakis; Robin A Pixley; Irma Isordia-Salas; Robert W Colman; Klaus T Preissner
Journal:  J Biol Chem       Date:  2002-06-24       Impact factor: 5.157

8.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.

Authors:  Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

9.  Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom
Journal:  Am J Med       Date:  2002-12-01       Impact factor: 4.965

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  3 in total

1.  Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure.

Authors:  Romil R Parikh; Aaron R Folsom; Jeffrey R Misialek; Wayne D Rosamond; Patricia P Chang; Weihong Tang; Mary Cushman
Journal:  Thromb Res       Date:  2019-08-22       Impact factor: 3.944

2.  Kininogen supports inflammation and bacterial spreading during Streptococccus Pyogenes Sepsis.

Authors:  Juliane Köhler; Claudia Maletzki; Dirk Koczan; Marcus Frank; Armin Springer; Carolin Steffen; Alexey S Revenko; A Robert MacLeod; Stefan Mikkat; Bernd Kreikemeyer; Sonja Oehmcke-Hecht
Journal:  EBioMedicine       Date:  2020-07-21       Impact factor: 8.143

Review 3.  The rebirth of the contact pathway: a new therapeutic target.

Authors:  Priyanka Srivastava; David Gailani
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.